CHRS
|Coherus BioSciences Inc
NASDAQ
USD 0.76
-0.03|-3.63%
Current Price
USD 0.76
Change
USD -0.03 (-3.63%)
P/E Ratio
1.82
Dividend Yield
Market Cap
92.75M
Volume
1.01M
Open
USD 0.78
Previous Close
USD 0.79
52-Week High
USD 2.43
52-Week Low
USD 0.66
About Coherus BioSciences Inc
Coherus BioSciences, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investi...
Sector:Healthcare
Industry:Biotechnology
CEO:Mr. Dennis M. Lanfear
Employees:221
Headquarters:Redwood City, USA
Website:www.coherus.com
Dividend History
Dividend Payments
| Declared Date | Record Date | Payment Date | Amount | Frequency |
|---|
Similar Companies
Explore Stocks by Sector
technology
finance
healthcare
Frequently Asked Questions